Biomarker studies have shown that expression of the T cell co-regulatory ligand PD-L1 on tumor cells correlates with clinical responsiveness to the PD-1 antibody nivolumab.
These findings point towards combinatorial therapy that brings together checkpoint blockade with a driver of tumor-specific immunity in cancer patients who have an ineffective anti-tumor immune response. The most straightforward approach to accomplish this would be to combine cancer vaccines that can increase the tumor specific T H 1 IFNJ secreting lymphocytes with anti-PD-1 blockade (6) .
With an extensive history of safety as well as expression of diverse, unbiased tumor antigens, lethally irradiated tumor cell vaccines engineered to secrete GM-CSF have the potential to be combined with immune checkpoint blockade antibodies in patients (7, 8) . Local GM-CSF can mobilize and recruit myeloid precursors into dendritic cells (DC), but this cytokine does not intrinsically induce DC activation (9) . Thus, one major limitation of GM-CSF secreting tumor vaccine (GM-vaccine) has been its limited capacity to activate antigen-presenting cells (APC) necessary for optimal tumor antigen presentation in the afferent arm of the immune system (10) . Towards improving the efficacy of antigen based cancer vaccines by stimulating plasmacytoid DC (pDC), Ali, et.al. formulated TLR9 agonist with tumor lysates and GM-CSF to induce improved in vivo efficacy (11) . To further optimize this combinatorial method, we developed a on April 12, 2017. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 8, 2014 ; DOI: 10.1158/0008-5472.CAN- strategy that incorporates GM-CSF, cell-based vaccine with unbiased tumor antigens, and multiple TLR agonists (11) (12) (13) (14) (15) (16) (17) that can activate both the conventional/classical (cDC) and the pDC in the innate immune system. We formulated glucopyranosyl lipid A (GLAa TLR4 agonist) and resiquimod (R848-a TLR7/8 agonist) -two agents found to be safe in patients -with a tumor cell based vaccine to create TLR agonists enhanced GMvaccine (TEGVAX) and studied its anti-tumor effects in an established, palpable B16 treatment model, which is resistant to most previously tested strategies of active immunotherapy (18) (19) (20) .
We first demonstrated that TEGVAX significantly enhanced DC activation, tumorspecific CTL activity, and in vivo anti-tumor responses in the systemic treatment of palpable B16 melanoma. However, no mice were cured, and we observed that this vaccination/treatment induced up-regulation of PD-L1 in tumors in an IFNJ dependent manner. Addition of PD-1 blockade to this vaccine resulted in regression of a significant proportion of tumor-bearing animals. , and C57BL/6 (Cg) Rag2tml (Rag2 -/-) mice were obtained from Drs. Franck Housseau (JHH). B16 and B16 GM-vaccine cells were cultured in RPMI1640 media containing 10% 'FCS, penicillin (100U/ml) and streptomycin (100U/ml). In PD-L1 experiments, B16 were cultured with serum free media. CD11c+ cells were isolated by anti-mouse CD11c microBeads (MACS, Miltenyi Biotec). CD4 depleting GK1.5 antibody and CD8 depleting 2.43 (Bio X Cell) at 200μg/dose were injected intraperitoneally (i.p.) every 2 days. Hybridoma expressing blocking anti-PD-1 antibody (clone G4) was obtained from Dr. Charles Drake (JHH).
Materials and Methods

Mice
Vaccine preparation: GLA at 1.0 mg/ml and R848 at 0.2 mg/ml were prepared in 10% (w/v) squalene oil-in-water emulsion vehicle (Immune Design, Seattle, WA). GLA/R848 dissolved in emulsion was incubated with lethally irradiated (150Gy) GM-vaccine cells at 4 deg C for 0.5-2 hours and washed 4x with PBS. This GM-vaccine formulated with In vivo cytotoxic T-lymphocyte (CTL) assay: Splenocytes were labeled with 0.5μM and 5μM carboxyfluorescein succinimidyl ester (CFSE-Molecular Probes). The 5μM CFSE labeled cells were pulsed with 10μg/ml P15E (KSPWFTTL) peptide. The 0.5μM CFSE labeled cells pulsed with β-gal (TPHPARIGL) peptide. Mice were injected intravenously (i.v.) with a 1:1 mixture of these cells, and the splenocytes were isolated after 24 hours and analyzed by flow cytometry. Antigen-specific killing was calculated using the following formula: (1-% of CFSE P15E /% of CFSE β-gal ) X 100. Bruker MRI using birdcage volume resonator using T2 weighted multi-gradient echo sequence. Image parameters were: FOV=2.2x2.2 cm, Matrix size=256x192, TR=500 ms, TE=3.1 ms, slice thickness=0.5mm and 12 slices. For quantification, regions of interest (ROI) were drawn on the lymph nodes and adjacent muscle tissue as internal controls.
For each ROI for every slice, pixel intensity histogram was plotted with the lowest pixel intensity in the control muscle tissue as the threshold, and quantitated as described previously (10).
Statistical Analysis:
We used paired t-test to calculate two-tailed p value to estimate statistical significance of differences between two treatment groups using Excel software.
Results
TEGVAX increased DC activation as well as IFNJ J secreting T-cells, but still failed to induce regression of established tumor.
We first formulated TEGVAX that can secrete DC recruiting GM-CSF and activate these DC via multiple TLR agonists to prime tumor specific T-cells. GM-vaccine indeed increased the abundance of CD11c+ DC at the site of vaccine injection ( Figure   1A ). Using the magnetovaccination MRI method to quantitate the number of endogenous APC with endocytosed surrogate tumor antigen (ferromagnetic label) from the vaccine cells, we found that GM-vaccine treated mice had significantly increased APC trafficking to the DLN ( Figure 1B) (21) . We then tested whether GLA and R848 formulated into We tested TEGVAX with established B16 tumors in a therapeutic model of palpable disease. As shown in Figure 1D , mice that received TEGVAX displayed lower tumor growth rate. Both GM-vaccine alone and TLR agonists alone had some modest slowing of the tumor growth, but the combination treatment produced the best in vivo anti-tumor response. In order to assess whether T-cells were important for TEGVAX's anti-tumor response, we performed vaccine treatment assays with Rag2 -/-mice and this anti-tumor response was abrogated in these mice ( Figure 1D ). We also determined that the anti-tumor effect of TEGVAX was completely abrogated in MyD88/TRIF double knockout mice, ensuring that TLR signaling was critical for its efficacy ( Figure 1D ). To assess whether this anti-tumor response can apply to different tumor types and murine strains, we also tested TEGVAX in the SCCFVII squamous cell carcinoma model in C3H mice as well as CT26 colon carcinoma model in Balb/c mice with comparable results, (Figure 2A ). We also performed this treatment assays with multiple TEGVAX treatments in the B16 model to improve this in vivo response, but no tumor regression was noted despite the decreased growth rate of the tumor ( Figure 2B ).
TEGVAX increased lymphocytic infiltration into the tumor microenvironment as well as tumor specific CTL responses.
When we examined the tumor microenvironment of these treated mice, increased regions of focal necrosis were found with TEGVAX treatment in comparison to those treated with GM-vaccine or controls ( Figure 3A,B) . Immunohistochemistry with CD4 and CD8 antibodies showed that TEGVAX treated tumor had significantly increased infiltrating CD4 and CD8 cells within the tumor tissue in comparison to the vaccine controls ( Figure 3C,D) . Based on the adaptive resistance hypothesis (3), we sought to determine whether the anti-tumor activity of TEGVAX could be dampened by the induction of PD-L1 in the tumor cells from the IFNJ secreting tumor specific TILs in the tumor microenvironment.
As described by others, we found that B16 cells treated in vitro with IFNJ can induce the expression of PD-L1 ( Figure 5A ). When we examined the TIL from TEGVAX treated mice, we noted an increased level of IFNJ secreting CD4 and CD8 in the tumor microenvironment ( Figure 5B ). We also noted co-localization of PD-L1 and CD8 T-cells in the tumor microenvironment (Supplemental Figure 1) . To test whether these increased 
with known formulations of vaccines. We saw no outgrowth of initially palpable B16 tumors that regressed even 2 months after the initiation of treatments, and a secondary challenge did not show any tumor growth ( Figure 6A,B) . Moreover, we did not need to It should be reiterated that all the components of TEGVAX/anti-PD-1 have been tested in patients to be relatively safe. With its demonstration as a potent anti-tumor agent by itself, TEGVAX in combination with anti-PD-1 antibody has high translational potential for clinical trials. GLA and R848 were initially selected because these adjuvants significantly induced enhanced anti-tumor cytokine profiles compared to other TLR agonists, and both have been tested in patients to be safe (17, (29) (30) (31) . We previously demonstrated an in vivo response with intratumoral injection using GM-vaccine formulated with LPS, but now we report a much more potent response with TEGVAX, a therapeutic vaccine administered distant from the site of established tumor (32) . The mechanisms that underlie the intratumoral injection in comparison to the systemic injection in these treatment models are different, but cumulatively, these experiments demonstrate that TLR agonists formulated with a cellular vaccine injected intratumorally or systemically are unlikely to have a pro-carcinogenic effect (17, (33) (34) (35) (36) .
Immune evasion mechanisms of the established tumor are multifactorial, and we have not addressed the role of stromal tissue (37, 38) or myeloid cells (MDSC or macrophages) (39, 40) A. TEGVAX induced anti-tumor response in palpable CT26 colon carcinoma and palpable SCCFVII tongue carcinoma models compared to controls (**P<0.01). CT26-GM and SCCFVII-GM vaccine was prepared as described previously (43, 44) . All the experiments were replicated at least 3 times. 
